Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos

Background: Hemolytic-uremic syndrome (HUS) is characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Aim: To describe the characteñstics ofpatients with the diagnosis ofHUS in Chile, and to identify the most reliable early predictors oímorbidity and moñality....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zambrano O,Pedro, Delucchi B,Angela, Cavagnaro S,Felipe, Hevia J,Pilar, Rosati M,María Pía, Lagos R,Elizabeth, Nazal Ch,Vilma, González C,Claudia, Barrera B,Patricia, Alvarez L,Enrique, Pinto S,Viola, Salas del C,Paulina, Cano Sen,Francisco, Contreras M,Angélica, Galanti de la P,Mónica, Gana A,Juan Cristóbal, Zamorano C,Julio, Espinoza B,Amelia, Dreves R,Patricia, Pereira M,Jaime, Bidegain S,Antonia, Pasten P,Erna, Yáñez P,Leticia, Cerda F,Verónica, Rodríguez S,Eugenio, Aglony I,Marlene, Gutiérrez I,Elisa, Salas P,Francisca, Figueroa Y,Sonia, Valenzuela A,Marcela, Grandy H,Jean, Guerra A,Boris, Lapadula A,Michelangelo, Reutter de la M,Paula, Gallardo T,Vivian, Maldonado S,Douglas, Azocar P,Marta, Cavada Ch,Gabriel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2008
Materias:	Escherichia coli Hemolytic-uremic syndrome Kidney failure, acute
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001000002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872008001000002
record_format	dspace
spelling	oai:scielo:S0034-988720080010000022009-01-15Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticosZambrano O,PedroDelucchi B,AngelaCavagnaro S,FelipeHevia J,PilarRosati M,María PíaLagos R,ElizabethNazal Ch,VilmaGonzález C,ClaudiaBarrera B,PatriciaAlvarez L,EnriquePinto S,ViolaSalas del C,PaulinaCano Sen,FranciscoContreras M,AngélicaGalanti de la P,MónicaGana A,Juan CristóbalZamorano C,JulioEspinoza B,AmeliaDreves R,PatriciaPereira M,JaimeBidegain S,AntoniaPasten P,ErnaYáñez P,LeticiaCerda F,VerónicaRodríguez S,EugenioAglony I,MarleneGutiérrez I,ElisaSalas P,FranciscaFigueroa Y,SoniaValenzuela A,MarcelaGrandy H,JeanGuerra A,BorisLapadula A,MichelangeloReutter de la M,PaulaGallardo T,VivianMaldonado S,DouglasAzocar P,MartaCavada Ch,Gabriel Escherichia coli Hemolytic-uremic syndrome Kidney failure, acute Background: Hemolytic-uremic syndrome (HUS) is characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Aim: To describe the characteñstics ofpatients with the diagnosis ofHUS in Chile, and to identify the most reliable early predictors oímorbidity and moñality. Material and methods: The clinical records ofpatients with HUS aged less than 15 years, attended between January 1990 and December 2003 in 15 hospitals, were reviewed. Demographic, clinical, biochemical, hematological parameters, morbidity and mortality were analyzed. Results: A cohort of 587 patients aged 2 to 8 years, 48% males, was analyzed. Ninety two percent had diarrhea. At the moment of diagnosis, anuria was observed in 39% of the patients, hypertension in 45% and seizures in 17%. Forty two percent required renal replacement therapy (RRT) and perítoneal dialysis was used in the majoríty of cases (78%). The most frequently isolated etiological agentwas Escherichia coli. Mortality rate was 2.9% in the acute phase of the disease and there was a positive correlation between mortality and anuria, seizures, white blood cell count (WCC) >20.000/mm³ and requirements of renal replacement therapy (p <0.05). Twelve percent of patients evolved to chronic renal failure and the risk factors during the acute phase were the need for renal replacement therapy, anuria, WCC >20.000/mm³, seizures and hypertension. Conclusions: The present study emphasizes important clinical and epidemiological aspeets ofHUSin a Chilean pediatricpopulation.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.10 20082008-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001000002es10.4067/S0034-98872008001000002
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Escherichia coli Hemolytic-uremic syndrome Kidney failure, acute
spellingShingle	Escherichia coli Hemolytic-uremic syndrome Kidney failure, acute Zambrano O,Pedro Delucchi B,Angela Cavagnaro S,Felipe Hevia J,Pilar Rosati M,María Pía Lagos R,Elizabeth Nazal Ch,Vilma González C,Claudia Barrera B,Patricia Alvarez L,Enrique Pinto S,Viola Salas del C,Paulina Cano Sen,Francisco Contreras M,Angélica Galanti de la P,Mónica Gana A,Juan Cristóbal Zamorano C,Julio Espinoza B,Amelia Dreves R,Patricia Pereira M,Jaime Bidegain S,Antonia Pasten P,Erna Yáñez P,Leticia Cerda F,Verónica Rodríguez S,Eugenio Aglony I,Marlene Gutiérrez I,Elisa Salas P,Francisca Figueroa Y,Sonia Valenzuela A,Marcela Grandy H,Jean Guerra A,Boris Lapadula A,Michelangelo Reutter de la M,Paula Gallardo T,Vivian Maldonado S,Douglas Azocar P,Marta Cavada Ch,Gabriel Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
description	Background: Hemolytic-uremic syndrome (HUS) is characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Aim: To describe the characteñstics ofpatients with the diagnosis ofHUS in Chile, and to identify the most reliable early predictors oímorbidity and moñality. Material and methods: The clinical records ofpatients with HUS aged less than 15 years, attended between January 1990 and December 2003 in 15 hospitals, were reviewed. Demographic, clinical, biochemical, hematological parameters, morbidity and mortality were analyzed. Results: A cohort of 587 patients aged 2 to 8 years, 48% males, was analyzed. Ninety two percent had diarrhea. At the moment of diagnosis, anuria was observed in 39% of the patients, hypertension in 45% and seizures in 17%. Forty two percent required renal replacement therapy (RRT) and perítoneal dialysis was used in the majoríty of cases (78%). The most frequently isolated etiological agentwas Escherichia coli. Mortality rate was 2.9% in the acute phase of the disease and there was a positive correlation between mortality and anuria, seizures, white blood cell count (WCC) >20.000/mm³ and requirements of renal replacement therapy (p <0.05). Twelve percent of patients evolved to chronic renal failure and the risk factors during the acute phase were the need for renal replacement therapy, anuria, WCC >20.000/mm³, seizures and hypertension. Conclusions: The present study emphasizes important clinical and epidemiological aspeets ofHUSin a Chilean pediatricpopulation.
author	Zambrano O,Pedro Delucchi B,Angela Cavagnaro S,Felipe Hevia J,Pilar Rosati M,María Pía Lagos R,Elizabeth Nazal Ch,Vilma González C,Claudia Barrera B,Patricia Alvarez L,Enrique Pinto S,Viola Salas del C,Paulina Cano Sen,Francisco Contreras M,Angélica Galanti de la P,Mónica Gana A,Juan Cristóbal Zamorano C,Julio Espinoza B,Amelia Dreves R,Patricia Pereira M,Jaime Bidegain S,Antonia Pasten P,Erna Yáñez P,Leticia Cerda F,Verónica Rodríguez S,Eugenio Aglony I,Marlene Gutiérrez I,Elisa Salas P,Francisca Figueroa Y,Sonia Valenzuela A,Marcela Grandy H,Jean Guerra A,Boris Lapadula A,Michelangelo Reutter de la M,Paula Gallardo T,Vivian Maldonado S,Douglas Azocar P,Marta Cavada Ch,Gabriel
author_facet	Zambrano O,Pedro Delucchi B,Angela Cavagnaro S,Felipe Hevia J,Pilar Rosati M,María Pía Lagos R,Elizabeth Nazal Ch,Vilma González C,Claudia Barrera B,Patricia Alvarez L,Enrique Pinto S,Viola Salas del C,Paulina Cano Sen,Francisco Contreras M,Angélica Galanti de la P,Mónica Gana A,Juan Cristóbal Zamorano C,Julio Espinoza B,Amelia Dreves R,Patricia Pereira M,Jaime Bidegain S,Antonia Pasten P,Erna Yáñez P,Leticia Cerda F,Verónica Rodríguez S,Eugenio Aglony I,Marlene Gutiérrez I,Elisa Salas P,Francisca Figueroa Y,Sonia Valenzuela A,Marcela Grandy H,Jean Guerra A,Boris Lapadula A,Michelangelo Reutter de la M,Paula Gallardo T,Vivian Maldonado S,Douglas Azocar P,Marta Cavada Ch,Gabriel
author_sort	Zambrano O,Pedro
title	Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
title_short	Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
title_full	Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
title_fullStr	Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
title_full_unstemmed	Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos
title_sort	síndrome hemolítico urémico en chile: presentación clínica, evolución y factores pronósticos
publisher	Sociedad Médica de Santiago
publishDate	2008
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008001000002
work_keys_str_mv	AT zambranoopedro sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT delucchibangela sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT cavagnarosfelipe sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT heviajpilar sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT rosatimmariapia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT lagosrelizabeth sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT nazalchvilma sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT gonzalezcclaudia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT barrerabpatricia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT alvarezlenrique sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT pintosviola sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT salasdelcpaulina sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT canosenfrancisco sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT contrerasmangelica sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT galantidelapmonica sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT ganaajuancristobal sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT zamoranocjulio sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT espinozabamelia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT drevesrpatricia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT pereiramjaime sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT bidegainsantonia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT pastenperna sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT yanezpleticia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT cerdafveronica sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT rodriguezseugenio sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT aglonyimarlene sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT gutierrezielisa sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT salaspfrancisca sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT figueroaysonia sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT valenzuelaamarcela sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT grandyhjean sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT guerraaboris sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT lapadulaamichelangelo sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT reutterdelampaula sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT gallardotvivian sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT maldonadosdouglas sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT azocarpmarta sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos AT cavadachgabriel sindromehemoliticouremicoenchilepresentacionclinicaevolucionyfactorespronosticos
_version_	1718436406215311360

Síndrome hemolítico urémico en Chile: presentación clínica, evolución y factores pronósticos

Ejemplares similares